42 results about "Uveitis" patented technology

Described herein are modified monoterpene TRPM8 activating compounds. In particular, provided herein are compounds that affect intracellular ion channel function, and are useful as or in conjunction with therapeutic agents. The compounds provided herein are useful in the treatment of a variety of diseases and disorders, including inflammatory eye diseases (e.g., uveitis), cardiovascular diseases, inflammatory diseases, and diseases characterized by aberrant hyperplasia (e.g., cancer).

The invention is concerned with a method of predicting response to an IL-6 angatonist such as anti-IL-6 antibody by determing the concentration of IL-6 in human aqueous humor. The invention is also concerned with an IL-6 angatonist for use in treatment of uveitis or uveitic macular edema.

The present invention belongs to the technical field of medicine, and in particular relates to a novel aromatic ring derivative containing an amide substitution or a pharmaceutically acceptable salt thereof. The diseases comprise, but are not limited to, inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, and uveitis. The structure of the compound of formula I is as described in the claims and the description. The aromatic ring derivative containing an amide substitution provided in the present invention is used as a novel TYK2 inhibitor, has a good TYK2 inhibitory effect, has a good therapeutic effect in an in vivo model of psoriasis and asthma animals, and has good druggability, high stability and good safety.

The present invention relates to a method of predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The invention also relates to an IL-6 antagonist for use in the treatment of uveitis or uveitis macular edema.

The invention belongs to the technical field of biology, and relates to a construction method of a renal tubular interstitial nephritis-uveitis syndrome mouse model. Comprising the following steps: anesthetizing a mouse; carrying out subcutaneous injection on photoreceptor intercellular vitamin A binding proteins and a complete Freund's adjuvant on the front neck, the thighs on the two sides and the back of the anesthetized mouse, and carrying out active immunization; and performing intraperitoneal injection on the actively immunized mouse by adopting pertussis toxin, and performing final immunization. According to the invention, the renal tubular interstitial nephritis-uveitis syndrome mouse model is successfully constructed, so that a foundation is laid for subsequent pathological mechanism research of the disease, and a support can be provided for further development of medicine research for treating the disease.

The present application provides an acesulfame implant which is stable, safe and can achieve at least 6 months of sustained release, can effectively treat various eye diseases including but not limited to glaucoma, cataract, retinal vein obstruction (RVO), uveitis, diabetic macular edema (DME) and age-related macular degeneration (wAMD and nAMD), etc., avoids repeated administration, reduces the formation of side effects, reduces the cost of drug use, and meets the high stability required by drug preparation in production, storage and transportation, has good application prospect, and meets the unmet clinical needs.

The invention belongs to the technical field of medicines, and particularly relates to a novel amide-substituted aromatic ring derivative or pharmaceutically acceptable salt thereof, which comprises but is not limited to inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, uveitis and the like. The structure of the compound shown in the formula I is shown in the claims and the specification. As a novel TYK2 inhibitor, the amide-substituted aromatic ring derivative provided by the invention has a good TYK2 inhibition effect, has a good treatment effect in an animal in-vivo model of psoriasis and asthma, and has good druggability, high stability and good safety.

The present invention relates to superoxide dismutase and uses thereof for preventing or treating diabetic retinopathy or uveitis. The superoxide dismutase according to the present invention can be effectively used in the prevention or treatment of diabetic retinopathy or uveitis, particularly through oral administration.

The present disclosure relates to a compound of Chemical Formula I or II, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof. Further, the present disclosure relates to a pharmaceutical composition for preventing or treating various ophthalmic diseases such as diabetic retinopathy, glaucoma, uveitis, wet and dry macular degeneration, and age-related macular degeneration, including the compound of Chemical Formula I or II, the solvate, the stereoisomer, or the pharmaceutically acceptable salt thereof as an active ingredient. A novel low molecular compound of the present disclosure exhibits an excellent effect in preventing and improving various ophthalmic diseases caused by retinal degeneration by inhibiting BET proteins to improve inflammation caused by retinal damage caused by epigenetic changes.

The invention relates to an application of prunella vulgaris phenolic acid in preparation of a product for preventing, treating and / or relieving liver injury complicated with uveitis. Researches show that prunella vulgaris phenolic acid improves the symptoms such as vasodilatation, iris congestion and pupil tightening, obviously reduces the eye score, can effectively improve D-GalN / LPS induced retinopathy, effectively reduces the content of ALT and AST in serum and improves D-GalN / LPS induced liver injury, and it is indicated that prunella vulgaris phenolic acid can relieve and treat liver injury combined uveitis. The application provides a new application for prunella vulgaris phenolic acid, and provides a new product for preventing, treating and / or relieving D-GalN / LPS induced liver injury combined uveitis at the same time.

The application discloses application of NAMPT as a target point in preparation of a medicine for treating uveitis, wherein the medicine contains a NAMPT inhibitor, the NAMPT inhibitor is FK866, and the NAMPT inhibitor is used for inhibiting expression or activity of NAMPT, thereby down-regulating CD4 + The Hif1a expression level of T cells reestablishes the Teff / Treg balance, and inhibits occurrence and development of uveitis, thereby providing a brand-new drug target for treatment of uveitis. Meanwhile, the application verifies that the NAMPT-HIF1a axis has conservation and potential treatment value in uveitis through experiments, proves that NAMPT can become a potential treatment target of uveitis, and proposes that a NAMPT inhibitor is used for preparing the medicine for treating uveitis, thereby laying a solid theoretical and experimental foundation for development of a new generation of targeted medicine for treating uveitis.

The present disclosure relates to a compound of Chemical Formula I, a solvate, a stereoisomer or a pharmaceutically acceptable salt thereof. Further, the present disclosure relates to a pharmaceutical composition for preventing or treating various ophthalmic such diseases as diabetic retinopathy, glaucoma, uveitis, wet and dry macular degeneration, and age-related macular degeneration, including the compound of Chemical Formula I, the solvate, the stereoisomer, or the pharmaceutically acceptable salt thereof as an active ingredient. A novel low molecular compound of the present disclosure exhibits an excellent effect in preventing and improving various ophthalmic diseases caused by retinal degeneration by inhibiting BET proteins to improve inflammation caused by retinal damage caused by epigenetic changes.

The invention relates to the technical field of biological medicine, in particular to application of MAGT1 small interfering RNA in preparation of medicine for treating uveitis, the MAGT1 small interfering RNA is RNA for interfering and reducing the expression quantity of MAGT1, the MAGT1 small interfering RNA provided by the invention can efficiently knock down the expression quantity of MAGT1 protein, down-regulate the proportion of Th1 cells and Th17 cells in CD4 + T cells and up-regulate the proportion of Treg cells, and the MAGT1 small interfering RNA can be used for preparing medicine for treating uveitis. According to the present invention, with the application of the pharmaceutical composition, the inflammatory reaction of uveitis is relieved, especially the treatment effect on the Vogt-Salix babylonica original field syndrome is provided, the supplement is provided for the uveitis pathogenesis, and the new strategy is provided for the target treatment of the uveitis.

The invention discloses an application of APOE as a target in preparation of a medicine for preventing and / or treating uveitis, the medicine comprises an APOE inhibitor, and the APOE inhibitor is used for inhibiting expression or activity of APOE protein so as to reduce microglial cell mediated inflammatory response. The invention discloses a key effect of APOE in uveitis pathogenesis, especially in microglial cell activation, for the first time, and provides a brand new drug target for treatment of uveitis; the inhibitor aiming at APOE can intervene in abnormal activation of microglial cells from the source, and possibly has better specificity and fewer side effects than a traditional immunosuppressor; meanwhile, the invention lays a solid theoretical and experimental foundation for developing a new generation of drugs for targeted therapy of uveitis.

The invention belongs to the technical field of biological medicine, and particularly relates to a soluble microneedle patch for in-situ drug delivery of trabecular meshwork tissue and a preparation method and application of the soluble microneedle patch. The soluble microneedle patch comprises a fan-ring-shaped backing and a microneedle array arranged on the fan-ring-shaped backing; the micro-needle and the fan-ring-shaped backing are both prepared from polyvinyl alcohol (PVA), the PVA concentration for preparing the micro-needle and the fan-ring-shaped backing is 5%-25%, and the PVA concentration is obtained by weighing 0.5 g-2. 5 g of PVA powder and dissolving the PVA powder in 10 mL of pure water or PBS. The microneedle patch is suitable for delivery of various types of drugs, is expected to be used for treatment of various eye diseases including glaucoma, ocular hypertension, cataract, uveitis, conjunctivitis, xerophthalmia and the like, and has important clinical application value and commercial value.

The invention provides pharmaceutical compositions comprising cyclosporine dissolved in a semifluorinated alkane for use in the treatment of uveitis.

The invention discloses application of oroxylum indicum total flavonoids in preparation of a medicine for treating uveitis. Experiments prove that the eye drops taking the oroxylum indicum total flavonoids or the oroxylin A as the active ingredient can reduce the uveitis eye inflammation and retina injury degree and reduce the infiltration quantity of inflammatory cells. The oroxylum indicum general flavone is taken as an oral medicine, so that inflammatory infiltration cells of a vitreous cavity and an iris-ciliary body can be reduced, bleeding symptoms can be effectively improved, hyperplasia of iris-ciliary body tissues can be inhibited, and infiltration of leukocytes of aqueous humor in mouse eyes can be effectively inhibited.

The invention belongs to the technical field of medicinal chemistry, and particularly relates to a novel glucocorticoid and a preparation method and application thereof, the novel glucocorticoid comprises a compound of a formula I, an optical isomer of the compound, a medicinal salt of the compound or a solvate of the compound, and the structural formula of the compound of the formula I is shown in the description. The compound provided by the invention has the advantages of high plasma removal rate, short half-life period, low systemic drug exposure and higher target selectivity to a glucocorticoid receptor (GR), and can obviously reduce side effects caused by systemic absorption of a glucocorticoid drug. The compound has remarkable anti-inflammatory activity on animal asthma, uveitis, xerophthalmia, inflammatory bowel disease, psoriasis and the like. The compound provided by the invention has good safety, no abnormal intraocular pressure is detected when the compound is continuously administered to the eyes of guinea pigs, and no obvious abnormal epidermal layer thickness occurs after the compound is continuously administered to the skin of rats.

A non-invasive diagnostic system is disclosed that integrates Raman spectroscopy with Artificial Intelligence (AI) to detect, classify, and quantify biomarkers and pharmacologic agents in the aqueous humor of the anterior chamber of the eye. The system includes a handheld or slit lamp-mounted Raman probe, a spectral acquisition and preprocessing pipeline, and an AI analysis engine trained to recognize disease-associated molecular signatures. The platform supports real-time diagnosis of glaucoma, uveitis, and other anterior segment conditions, enabling early detection, risk stratification, and longitudinal monitoring. The AI component is capable of incorporating newly discovered biomarkers and contextual factors such as medication use, diurnal variation, and anatomical sampling location. Diagnostic outputs are presented with confidence scores and may include disease classification, biomarker trends, or pharmacologic exposure levels. Built-in safety protocols ensure ANSI Z136.1-compliant laser use, while explainable AI tools and federated learning enhance transparency and clinical adaptability.

The present invention relates to a method for predicting response to an IL-6 antagonist, such as an anti-IL-6 antibody, by determining the concentration of IL-6 in human aqueous humor. The present invention also relates to an IL-6 antagonist for use in treating uveitis or uveitic macular edema.

The invention discloses an application of PPIF as a target in preparation of a medicine for preventing and / or treating uveitis, the medicine comprises a PPIF inhibitor, and the PPIF inhibitor is used for inhibiting expression or activity of PPIF protein so as to reduce microglial cell mediated inflammatory response. The invention discloses the key effect of PPIF in the uveitis pathogenesis, especially in microglial cell activation, for the first time, and provides a brand new drug target for treatment of uveitis; an inhibitor aiming at PPIF can intervene in abnormal activation of microglial cells from the source, and possibly has better specificity and fewer side effects compared with a traditional immunosuppressor; meanwhile, the invention lays a solid theoretical and experimental foundation for developing a new generation of drugs for targeted therapy of uveitis.

The invention relates to the field of biological medicine, in particular to a BU (Behcet's disease uveitis) biomarker screening method based on an intestinal microorganism metagenome, a screened BU biomarker combination and application of the biomarker combination in BU diagnosis. The kit is especially suitable for early diagnosis of BU and differential diagnosis of other systemic immune diseases. The biomarker combination consists of 24 intestinal strains, and is obtained by analyzing excrement metagenome data of BU patients, other systemic immune disease patients and healthy controls through diversity analysis, LEfSe screening and ROC verification. The marker has high sensitivity and specificity, can effectively distinguish BU from healthy people and diseases such as VKH, AS, RA, CD and UC, is suitable for developing a non-invasive BU diagnostic kit, and remarkably improves the clinical diagnosis efficiency.

The present invention relates to a composition comprising a peptide derived from myelin basic protein (MBP) peptide for use in treating or preventing uveitis in a subject

The present invention belongs to the field of medicine, and in particular relates to novel aromatic ring derivatives having amide substitutions or pharmaceutically acceptable salts thereof. Diseases include, but are not limited to, inflammatory or autoimmune diseases such as psoriasis, psoriatic arthritis, dermatitis, lupus erythematosus, inflammatory bowel disease, hidradenitis suppurativa, rheumatoid arthritis, and uveitis. The structure of the compound of Formula I is as set forth in the claims and the specification. The aromatic ring derivatives having amide substitutions provided by the present invention can be used as novel TYK2 inhibitors, and have good TYK2 inhibitory activity, good therapeutic effects in in vivo animal models of psoriasis and asthma, and excellent drug discoverability, high stability, and good safety.

The invention relates to the technical field of biological medicines, in particular to nanoparticles as well as a preparation method and application thereof. The invention provides the nano-particles prepared by taking a thiol compound as an antibody carrier material, the permeation efficiency of the antibody in eyes is remarkably improved by the nano-particles through a thiol exchange pathway, and the antibody can reach deep tissues of the eyes through eye drop administration, such as cornea, cornea, cornea and the like. The nano-particle delivery system can be enriched in eye posterior tissues such as retina and choroids, and the nano-particle delivery system shows a good treatment effect in corneal neovascularization eye diseases and uveitis.